Driving clinical impact
Faster, leaner, de-risked
Product portfolio
Galenicap is building a scalable, capital-efficient 'product engine' to rapidly develop well-validated, high-impact medicines. Our approach combines strategic product selection, agile development, and focused investment to accelerate the path toward clinical validation.
Currently, we are advancing 12 programs in various therapeutic indications, including CNS, oncology, cardiovascular conditions, infectious diseases, and women’s health.
Unlike most 505(b)(2) or hybrid projects that bring minimal innovation, Galenicap pioneers groundbreaking solutions with real clinical impact
Everyone counts
Our vision is to improve healthcare by expanding access to affordable, patient-centered medicines.
At Galenicap, we are deeply committed to responsible business practices rooted in strong governance and meaningful social impact. We champion health equity, fair medicine pricing, transparent leadership, and a culture of diversity and inclusion.
We are proud that our team members, collaborators, partners, and shareholders are united in upholding these values.
Latest news & events
Galenicap co-founded Aclathera BV, a specialty pharma dedciated to the development of new cancer treatments
March 28, 2025
Clozathera BV (a Galenicap company) completes financing round to support Phase 1 clinical trial for its lead product
January 6, 2025
Galenicap establishes drug repurposing collaboration with leading Danish university
​
September 2, 2024